Rimegepant

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 315 publications

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Journal: Neurology

Published: August 31, 2026

Reply to: Baseline severity is not treatment timing in acute rimegepant treatment for vestibular migraine.

Reply to: Baseline severity is not treatment timing in acute rimegepant treatment for vestibular migraine.

Journal: Cephalalgia : an international journal of headache

Published: August 19, 2026

Baseline severity is not treatment timing in acute rimegepant treatment for vestibular migraine.

Baseline severity is not treatment timing in acute rimegepant treatment for vestibular migraine.

Journal: Cephalalgia : an international journal of headache

Published: August 19, 2026

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Journal: Headache

Published: July 29, 2026

Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project).

Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project).

Journal: Cephalalgia : an international journal of headache

Published: July 06, 2026

Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec® ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine

Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec® ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: July 01, 2026

Effectiveness and clinical predictors of rimegepant for acute vertigo in vestibular migraine: A real-world cohort study.

Effectiveness and clinical predictors of rimegepant for acute vertigo in vestibular migraine: A real-world cohort study.

Journal: Cephalalgia : an international journal of headache

Published: June 30, 2026

A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US.

A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US.

Journal: Cephalalgia : an international journal of headache

Published: June 11, 2026

CGRP reception potentiates anxiety in an influenza A derived immune engram.

CGRP reception potentiates anxiety in an influenza A derived immune engram.

Journal: bioRxiv : the preprint server for biology

Published: June 04, 2026

Migraine and depression: an important relationship

Migraine and depression: an important relationship

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: May 14, 2026

Glaucoma Risk Associated With Calcitonin Gene-Related Peptide Inhibitor Use in Migraine: A Multinational Cohort Study.

Glaucoma Risk Associated With Calcitonin Gene-Related Peptide Inhibitor Use in Migraine: A Multinational Cohort Study.

Journal: Neurology

Published: May 06, 2026

Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine : A Systematic Review of Randomized Controlled Trials.

Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine : A Systematic Review of Randomized Controlled Trials.

Journal: Annals of internal medicine

Published: May 04, 2026

Showing 1-12 of 315

Last Updated: 09/26/2026